Answers are grounded in this paper and cite their sources.
The AHEAD 3-45 Study will test whether with lecanemab (BAN2401) can slow the accumulation of tau and prevent the cognitive decline associated with AD during its preclinical stage. It is specifically targeting both the preclinical and the early preclinical (intermediate amyloid) stages of AD and is the first secondary prevention trial to employ plasma-based biomarkers to accelerate the screening process and potentially substantially reduce the number of screening PET scans.
No takes yet. Share an insight, caveat, or question.
Rafii et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: